VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CLLS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CLLSCellectis S.A.
$1.03$103M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCLLSBalance Sheet

Cellectis S.A. (CLLS) Balance Sheet

19Y historyFree accessUpdated daily

The company's financial position has deteriorated significantly, with the debt-to-equity ratio climbing to 1.81 in 2026Q1 from 0.61 in 2024Q2, reflecting increased reliance on debt to fund ongoing development.

Income StatementBalance SheetCash FlowRatios

CLLS Balance Sheet

Annual statement

CLLS Balance Sheet

Cellectis S.A. (CLLS) balance sheet — 19-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Total Current Assets184.42M236.24M287.07M233.01M143.81M225.43M315.36M391.52M487.64M323.22M311.79M365.4M160.51M27.54M51.47M70.63M47.57M74.76M48.14M42.73M
Cash & Short-Term Investments166.85M208.66M260.31M203.81M97.7M186.13M268.24M360.91M451.89M296.98M290.5M343.56M136.62M10.44M28.84M54.93M31.98M65.33M39.78M36.74M
Cash Only35.59M63.58M143.25M136.71M89.79M185.64M241.15M360.91M451.89M296.98M290.5M343.56M136.62M10.44M28.84M54.93M31.98M65.33M39.78M36.74M
Short-Term Investments131.26M145.08M117.06M67.11M7.91M499K27.09M0000000000000
Accounts Receivable13.64M25.32M23.04M23.13M17.57M31.07M19.19M15.29M22.07M4.57M3.63M16.55M19.55M15.68M20.19M14.88M12.07M4.78M5.03M4.01M
Days Sales Outstanding129.69126.68202.5911.18K334.59373.74137.22367.48632.6666.1531.09109.74271.28250.84264.91262.07210.07100.79124.29356.57
Inventory0000001.61M2.9M275K250K117.79K172.74K164.16K506.78K935.01K811.35K203.48K169.06K168.44K173.5K
Days Inventory Outstanding------300.4692.8236.6534.8325.4723.316.24218.17168.1190.8538.6526.5439.8642.88
Other Current Assets341K329K298K345K22.31M50K12.21M594K2.42M2.99M363K14.97M984.98K461.61K4.98M3.9M3.31M3.53M3.16M1.82M
Total Non-Current Assets82.95M88.48M96.48M101.27M117.41M156.65M154.11M75.95M13.2M9.66M18.89M7.48M6.83M16.57M63.64M61.26M21.66M16.58M12.69M11.14M
Property, Plant & Equipment53.99M62.45M75.86M92.74M107.9M148.27M145.52M69.32M10.04M7.23M16.86M5.51M3.17M5.34M7.25M8.58M5.2M1.27M1.99M1.48M
Fixed Asset Turnover0.94x1.17x0.55x0.01x0.18x0.20x0.35x0.22x1.27x3.49x2.53x9.98x8.29x4.27x3.84x2.42x4.03x13.61x7.43x2.77x
Goodwill00000000000001.51M38.03M00000
Intangible Assets1.12M535K1.11M672K718K1.85M1.58M1.11M1.27M1.43M1.34M1.05M1.25M7.63M5.2M45.63M5.29M22.92K5.03M4.01M
Long-Term Investments12.38M5.09M7.52M7.85M8.79M6.52M7.01M5.52M1.89M1M689.92K923.84K2.4M2.09M1.88M1.24M307.22K330.96K423.2K99.14K
Other Non-Current Assets25.86M20.02M11.6M-1K03K-1K5.52M-1K102K01.09K2.18M1.38K01.3K221.39K0
Total Assets267.37M324.72M383.54M334.27M261.22M382.08M469.47M467.47M500.84M332.88M330.68M372.88M167.34M44.11M115.11M131.89M69.23M91.34M60.83M53.87M
Asset Turnover0.18x0.22x0.11x0.00x0.07x0.08x0.11x0.03x0.03x0.08x0.13x0.15x0.16x0.52x0.24x0.16x0.30x0.19x0.24x0.08x
Asset Growth %-73.72%-15.34%14.74%27.97%-31.63%-18.62%0.43%-6.66%50.46%0.67%-11.32%122.83%279.34%-61.68%-12.72%90.5%-24.2%50.15%12.92%-
Total Current Liabilities134.96M145.75M166.27M155.14M62.99M49.35M52.02M62.6M46.87M43.53M56.04M84.12M91.04M32.2M28.36M26.96M17.02M15.44M12.78M8.18M
Accounts Payable18.2M17.28M18.66M19.07M21.46M23.76M24.61M29.26M15.88M9.46M9.72M7.23M11.92M13.39M14.46M25.39M15.79M9.38M7.48M0
Days Payables Outstanding437.74643.68741.93938.16923.084.7K4.6K937.622.12K1.32K2.1K974.961.18K5.77K2.6K2.84K3K1.47K1.77K-
Short-Term Debt1.31M18.16M4.84M5.16M4.97M2.25M00001.69M66K724.74K207.13K1.32M1.57M744.78K000
Deferred Revenue (Current)374.79M96.8M112.16M110.33M59K301K452K20.03M20.75M26.06M38.84M59.87M72.34M7.75M004.68M000
Other Current Liabilities9.97M13.51M13.37M2.72M16.16M2.16M7.21M4.95M2.86M2.02M1.46M10.19M4.51M6.32M3.17M-40.3K-4.19M10.02M5.3M1.54M
Current Ratio1.37x1.62x1.73x1.50x2.28x4.57x6.06x6.25x10.40x7.42x5.56x4.34x1.76x0.86x1.82x2.62x2.79x4.84x3.77x5.22x
Quick Ratio1.37x1.62x1.73x1.50x2.28x4.57x6.03x6.21x10.40x7.42x5.56x4.34x1.76x0.84x1.78x2.59x2.78x4.83x3.75x5.20x
Cash Conversion Cycle-308.05------4.17K-477.32-1.45K-1.22K-2.05K-841.91-891.31-5.3K-2.17K-2.49K-2.75K-1.35K-1.61K-
Total Non-Current Liabilities91.34M103.07M95.25M94.43M72.28M96.25M108.61M49.4M3.7M3.44M588.95K549.93K3.92M5.26M5.06M67.91M2.08M2.68M1.84M2.15M
Long-Term Debt52.66M74.01M43.99M28.44M13.57M18.77M24.22M00002.19K3.38M4.22M3.35M67.51M1.08M703.48K00
Capital Lease Obligations106.75M27.72M34.24M42.95M49.36M71.53M75.76M46.54M1.02M13K30K69.97K58.37K433.59K000000
Deferred Tax Liabilities000158K0000000000000000
Other Non-Current Liabilities14.85M1.33M17.02M22.88M9.35M5.96M8.63M2.85M2.68M3.43M560K474.25K483.97K612.39K1.71M396.61K1.01M1.97M1.84M2.15M
Total Liabilities226.3M248.82M252.51M249.57M135.28M145.6M160.63M112M50.57M46.98M56.63M84.67M94.95M37.46M33.42M94.86M19.1M18.12M14.62M10.33M
Total Debt84.57M119.9M91.46M85.06M75.77M100.87M106.68M47.61M1.35M34K1.76M2.17M4.48M5.61M5.67M69.08M1.82M2.62M00
Net Debt48.98M56.32M-51.79M-51.65M-14.02M-84.77M-134.47M-313.3M-450.54M-296.95M-288.74M-341.38M-132.13M-4.82M-23.17M14.15M-30.16M-62.71M-39.78M-36.74M
Debt / Equity2.06x1.58x0.70x1.00x0.60x0.43x0.35x0.13x0.00x0.00x0.01x0.01x0.06x0.84x0.07x1.87x0.04x0.04x--
Debt / EBITDA-1.98x-------------------
Net Debt / EBITDA-1.14x-------------------
Interest Coverage-8.85x-7.39x-3.93x-20.95x-25.04x-22.20x-14.01x-38.05x-122.11x-185.14x-10656.70x-1226.10x12.49x-84.70x-11.03x-40.01x-72.22x-1557.33x-264.62x-238.05x
Total Equity41.07M75.9M131.03M84.69M125.94M236.47M308.85M355.47M450.27M285.9M274.05M288.22M72.39M6.65M81.69M37.02M50.13M73.22M46.21M43.54M
Equity Growth %-170.59%-42.07%54.71%-32.75%-46.74%-23.43%-13.12%-21.05%57.49%4.33%-4.92%298.17%988.46%-91.86%120.64%-26.15%-31.54%58.45%6.13%-
Book Value per Share0.410.761.451.492.765.577.278.3811.048.017.658.352.760.324.102.623.555.183.273.08
Total Shareholders' Equity41.07M75.9M131.03M84.69M117.97M221.29M283.8M315.12M409.3M266.79M272.18M287.42M73.92M6.95M78.93M37.02M50.13M73.22M46.21M43.54M
Common Stock5.92M5.9M5.89M4.37M2.96M2.94M2.79M2.77M2.77M2.37M1.86M1.92M1.79M1.46M174.55M104.2M776.7K833.86K46.21M43.54M
Retained Earnings-303.93M-334.13M-329.61M-405.77M-439.5M-698.33M-587.03M-508.48M-405.32M-351.3M-229.77M-172.45M24.32K-84.28M-28.9M-67.18M-10.72M000
Treasury Stock000000000-297K-416K-201.17K-305.22K-568.92K-227.47K00000
Accumulated OCI-32.68M-33.32M-39.54M-36.69M-28.61M-18.02M-4.09M-22.64M-16.67M1.98M2.63M-1.78M-162.09M-94.22M-66.72M00-5.52M00
Minority Interest00007.97M15.18M25.05M40.35M40.97M19.11M1.87M792.64K-1.53M-298.27K2.76M00000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical Milestone Funding Dependency

Asset Base Erosion Amidst Losses

As reported in recent financial statements, Cellectis has seen its total assets contract from $407.1 million in 2024Q2 to $289.2 million by 2026Q1, a trend that reflects the persistent depletion of capital to fund ongoing clinical development in the absence of self-sustaining commercial revenue.

The consistent decline in total assets suggests that the company is consuming its resource base faster than it can replenish it through partnership milestones. This trajectory indicates a weakening balance sheet that may necessitate further external financing to maintain current operational levels.

Rising Leverage Amidst Capital Constraints

Based on the latest quarterly filings, the company's debt-to-equity ratio has deteriorated significantly, climbing from 0.61 in 2024Q2 to 1.81 in 2026Q1, which indicates an increasing reliance on debt financing to bridge the gap between high R&D burn and lumpy, milestone-dependent revenue inflows.

The shift toward higher leverage appears to be a necessity-driven response to the exhaustion of cash reserves rather than a strategic capital allocation decision. Investors should monitor whether this debt burden creates restrictive covenants that could limit future operational flexibility.

Diminishing Cash Runway and Buffer

According to the provided balance sheet data, cash and equivalents have fallen from a peak of $159.1 million in 2024Q3 to just $35.0 million in 2026Q1, signaling a rapid erosion of the liquidity buffer required to navigate the company's high-burn clinical trial environment.

The current ratio of 1.52 suggests that while the company maintains sufficient short-term assets to cover immediate liabilities, the absolute decline in cash reserves is concerning. This trend implies that the company's ability to withstand unexpected clinical delays or regulatory setbacks is becoming increasingly constrained.

Equity Quality Impacted by Deficits

As indicated by the company's reported figures, retained earnings have plummeted to a deficit of $351.9 million as of 2026Q1, reflecting the cumulative impact of years of heavy R&D investment that has yet to translate into a profitable, commercial-stage business model.

The erosion of equity highlights the significant value destruction inherent in the current clinical-stage development cycle. This persistent negative trend in retained earnings suggests that shareholders remain exposed to the risk of further dilution should the company need to raise additional capital to fund its pipeline.

Deferred Revenue as Liquidity Distortion

Analysis of the balance sheet reveals that deferred revenue remains a substantial liability at $93.1 million, which may provide a misleading sense of future stability if investors fail to account for the high cost of fulfilling these performance obligations over the coming periods.

While deferred revenue represents a commitment from partners, it also functions as a future operational burden that requires significant cash expenditure to satisfy. Relying on this metric as a proxy for future health may overlook the reality that these obligations are tied to expensive, high-risk clinical milestones.

CLLS — Frequently Asked Questions

Quick answers to the most common questions about buying CLLS stock.

What are the total assets of Cellectis S.A. (CLLS)?

As of 2025, Cellectis S.A. (CLLS) had total assets of $324.7M including $236.2M in current assets.

How much debt does Cellectis S.A. (CLLS) have?

Cellectis S.A. (CLLS) carries total debt of $119.9M, offset by $208.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Cellectis S.A.?

Cellectis S.A. (CLLS) has total shareholders' equity (book value) of $75.9M ($0.76 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Cellectis S.A.'s current ratio and liquidity?

Cellectis S.A. (CLLS) reported a current ratio of 1.62x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.